Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02071927 | Study of the Glutaminase Inhibitor CB-839 in Leukemia | completed | Phase 1 | 43 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 9, 2017 |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT01773408 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | completed | Phase 1 | 122 | Hoffmann-La RocheINDUSTRY | 7 | Jan 25, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT03005392 | Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 24 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 29, 2016 | clinicaltrials |
| NCT02861040 | Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02096289 | Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia(THORIDAL) | completed | Phase 1 | 13 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00874562 | Rapamycin in Relapsed Acute Lymphoblastic Leukemia | completed | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02968472 | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | unknown | Phase 1 | 30 | The First People's Hospital of YunnanOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01635296 | A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 43 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01641250 | A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 44 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Beijing Sanwater Biological Technology Co., Ltd.INDUSTRY | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02528877 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 1, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT02859948 | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01174888 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 34 | Alison WalkerOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | completed | Phase 1 / Phase 2 | 45 | Cellerant TherapeuticsINDUSTRY | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00316030 | Study of Bexarotene in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 54 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 8, 2016 | clinicaltrials |
| NCT00313053 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | Clare TwistOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT01075425 | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 41 | Virginia Commonwealth UniversityOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 4 | Apr 5, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT00529360 | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | completed | Phase 1 / Phase 2 | 32 | New York Medical CollegeOTHER | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01681537 | Lenalidomide Plus Chemotherapy for AML | completed | Phase 1 | 36 | Massachusetts General HospitalOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01455025 | Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia(PRIMAL) | terminated | Phase 1 | 11 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01398462 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 69 | JW PharmaceuticalINDUSTRY | 2 | Mar 8, 2016 | clinicaltrials |
| NCT00850382 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 89 | University of UlmOTHER | 2 | Mar 1, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02413021 | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | unknown | Phase 1 | 40 | Isfahan University of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT02040506 | A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML | completed | Phase 1 | 19 | Igenica Biotherapeutics, Inc.INDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01956630 | Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT | unknown | Phase 1 / Phase 2 | 25 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00984412 | Allo-Allo Tandem Bone Marrow Transplant (BMT)(AATT) | unknown | Phase 1 / Phase 2 | 15 | Hadassah Medical OrganizationOTHER | 1 | Feb 19, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2017source: clinicaltrials